Activities
OCTA20 Final Assessment Report is now available.
We are pleased to announce that the final assessment report for OTCA20 ‘Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)’,
OCTA20 Final Assessment Report is now available.
We are pleased to announce that the final assessment report for OTCA20 ‘Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)’,
OTCA18 Final Assessment Report is now available.
The final assessment report and related documents concerning OTCA18, ‘regional hyperthermia for high-risk soft tissue sarcoma treatment’, are now available. The assessed technology is regional
Open Call for Patient Input for a new Joint Assessment on a medicinal product for neuromyelitis optica spectrum (NMOSD) disorders.
Patient group input requested for a new Joint Assessment on a medicinal product for neuromyelitis optica spectrum disorders. EUnetHTA deems patient involvement very important in
PTJA07 Final Assessment Report is now available
We are pleased to announce that the Final Assessment Report for PTJA07 is now available, with supporting documentation, for access. Please follow this link for
EUnetHTA Magazine – Autumn 2019 – Now Available
We are pleased to publish the Autumn 2019 issue of EUnetHTA Magazine. Intended for improved accessibility on whichever device you use, this issue includes various
Minutes from the EMA-EUnetHTA July 2019 Meeting now available
The minutes from the EMA-EUnetHTA Bilateral Meeting, hosted by the EUnetHTA at the Zorginstituut Nederland (ZIN) in Diemen, Netherlands, on 4th July, 2019, are now
Open Call for Patient Input for a new Joint Assessment on a medicinal product for acute myeloid leukaemia.
Patient group input requested for a new Joint Assessment on a medicinal product for acute myeloid leukaemia. EUnetHTA deems patient involvement very important in
REQueST Tool and its vision paper are now available for access.
The Registry Evaluation and Quality Standards Tool (REQueST) aims to support HTA organisations and other actors in guiding and evaluating registries for effective usage in
PTJA12 – EUnetHTA is pleased to announce the start of the next Pharmaceutical Joint Assessment.
EUnetHTA is pleased to announce the start of the next Pharmaceutical Joint Assessment. PTJA12 addresses ‘Glasdegib indicated for the treatment of newly diagnosed de novo
